Cargando…
Content validity and psychometric properties of the inFLUenza Patient-Reported Outcome Plus (FLU-PRO Plus(©)) instrument in patients with COVID-19
PURPOSE: A well-defined and reliable patient-reported outcome instrument for COVID-19 is important for assessing symptom severity and supporting research studies. The InFLUenza Patient-Reported Outcome (FLU-PRO) instrument has been expanded to include loss of taste and smell in the FLU-PRO Plus, to...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879742/ https://www.ncbi.nlm.nih.gov/pubmed/36703019 http://dx.doi.org/10.1007/s11136-022-03336-3 |
_version_ | 1784878758046466048 |
---|---|
author | Keeley, Tom J. H. Satram, Sacha Ghafoori, Parima Reyes, Carolina Birch, Helen J. Raymond, Kimberly Gelhorn, Heather L. Kosinski, Mark Saucier, Cory D. Mitchell Foster, April Lopuski, Amanda Powers, John H. |
author_facet | Keeley, Tom J. H. Satram, Sacha Ghafoori, Parima Reyes, Carolina Birch, Helen J. Raymond, Kimberly Gelhorn, Heather L. Kosinski, Mark Saucier, Cory D. Mitchell Foster, April Lopuski, Amanda Powers, John H. |
author_sort | Keeley, Tom J. H. |
collection | PubMed |
description | PURPOSE: A well-defined and reliable patient-reported outcome instrument for COVID-19 is important for assessing symptom severity and supporting research studies. The InFLUenza Patient-Reported Outcome (FLU-PRO) instrument has been expanded to include loss of taste and smell in the FLU-PRO Plus, to comprehensively cover COVID-19 symptoms. Our studies were designed to evaluate and validate the FLU-PRO Plus among patients with COVID-19. METHODS: Two studies were conducted: (1) a qualitative, non-interventional, cross-sectional study of patients with COVID-19 involving hybrid concept elicitation and cognitive debriefing interviews; (2) a psychometric evaluation of the measurement properties of FLU-PRO Plus, using data from COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial—Intent to Care Early). RESULTS: In the qualitative interviews (n = 30), all 34 items of the FLU-PRO Plus were considered relevant to COVID-19, and participants determined the questionnaire was easily understood, well written, and comprehensive. In the psychometric evaluation (n = 845), the internal consistency reliability of FLU-PRO Plus total score was 0.94, ranging from 0.71 to 0.90 for domain scores. Reproducibility (Day 20–21) was 0.83 for total score, with domain scores of 0.67–0.89. Confirmatory factor analysis with the novel smell/taste domain demonstrated an acceptable fit to the data. CONCLUSION: The content, reliability, validity, and responsiveness of the FLU-PRO Plus in the COVID-19 population were supported. Our results suggest that FLU-PRO Plus is a content- and psychometrically-valid, fit-for-purpose measure which is easily understood by patients. FLU-PRO Plus is a suitable PRO measure for evaluating symptoms of COVID-19 and treatment benefit directly from the patient perspective. Trial Registration: ClinicalTrials.Gov: NCT04545060, September 10, 2020; retrospectively registered. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11136-022-03336-3. |
format | Online Article Text |
id | pubmed-9879742 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-98797422023-01-27 Content validity and psychometric properties of the inFLUenza Patient-Reported Outcome Plus (FLU-PRO Plus(©)) instrument in patients with COVID-19 Keeley, Tom J. H. Satram, Sacha Ghafoori, Parima Reyes, Carolina Birch, Helen J. Raymond, Kimberly Gelhorn, Heather L. Kosinski, Mark Saucier, Cory D. Mitchell Foster, April Lopuski, Amanda Powers, John H. Qual Life Res Article PURPOSE: A well-defined and reliable patient-reported outcome instrument for COVID-19 is important for assessing symptom severity and supporting research studies. The InFLUenza Patient-Reported Outcome (FLU-PRO) instrument has been expanded to include loss of taste and smell in the FLU-PRO Plus, to comprehensively cover COVID-19 symptoms. Our studies were designed to evaluate and validate the FLU-PRO Plus among patients with COVID-19. METHODS: Two studies were conducted: (1) a qualitative, non-interventional, cross-sectional study of patients with COVID-19 involving hybrid concept elicitation and cognitive debriefing interviews; (2) a psychometric evaluation of the measurement properties of FLU-PRO Plus, using data from COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial—Intent to Care Early). RESULTS: In the qualitative interviews (n = 30), all 34 items of the FLU-PRO Plus were considered relevant to COVID-19, and participants determined the questionnaire was easily understood, well written, and comprehensive. In the psychometric evaluation (n = 845), the internal consistency reliability of FLU-PRO Plus total score was 0.94, ranging from 0.71 to 0.90 for domain scores. Reproducibility (Day 20–21) was 0.83 for total score, with domain scores of 0.67–0.89. Confirmatory factor analysis with the novel smell/taste domain demonstrated an acceptable fit to the data. CONCLUSION: The content, reliability, validity, and responsiveness of the FLU-PRO Plus in the COVID-19 population were supported. Our results suggest that FLU-PRO Plus is a content- and psychometrically-valid, fit-for-purpose measure which is easily understood by patients. FLU-PRO Plus is a suitable PRO measure for evaluating symptoms of COVID-19 and treatment benefit directly from the patient perspective. Trial Registration: ClinicalTrials.Gov: NCT04545060, September 10, 2020; retrospectively registered. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11136-022-03336-3. Springer International Publishing 2023-01-27 2023 /pmc/articles/PMC9879742/ /pubmed/36703019 http://dx.doi.org/10.1007/s11136-022-03336-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Keeley, Tom J. H. Satram, Sacha Ghafoori, Parima Reyes, Carolina Birch, Helen J. Raymond, Kimberly Gelhorn, Heather L. Kosinski, Mark Saucier, Cory D. Mitchell Foster, April Lopuski, Amanda Powers, John H. Content validity and psychometric properties of the inFLUenza Patient-Reported Outcome Plus (FLU-PRO Plus(©)) instrument in patients with COVID-19 |
title | Content validity and psychometric properties of the inFLUenza Patient-Reported Outcome Plus (FLU-PRO Plus(©)) instrument in patients with COVID-19 |
title_full | Content validity and psychometric properties of the inFLUenza Patient-Reported Outcome Plus (FLU-PRO Plus(©)) instrument in patients with COVID-19 |
title_fullStr | Content validity and psychometric properties of the inFLUenza Patient-Reported Outcome Plus (FLU-PRO Plus(©)) instrument in patients with COVID-19 |
title_full_unstemmed | Content validity and psychometric properties of the inFLUenza Patient-Reported Outcome Plus (FLU-PRO Plus(©)) instrument in patients with COVID-19 |
title_short | Content validity and psychometric properties of the inFLUenza Patient-Reported Outcome Plus (FLU-PRO Plus(©)) instrument in patients with COVID-19 |
title_sort | content validity and psychometric properties of the influenza patient-reported outcome plus (flu-pro plus(©)) instrument in patients with covid-19 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879742/ https://www.ncbi.nlm.nih.gov/pubmed/36703019 http://dx.doi.org/10.1007/s11136-022-03336-3 |
work_keys_str_mv | AT keeleytomjh contentvalidityandpsychometricpropertiesoftheinfluenzapatientreportedoutcomeplusfluproplusinstrumentinpatientswithcovid19 AT satramsacha contentvalidityandpsychometricpropertiesoftheinfluenzapatientreportedoutcomeplusfluproplusinstrumentinpatientswithcovid19 AT ghafooriparima contentvalidityandpsychometricpropertiesoftheinfluenzapatientreportedoutcomeplusfluproplusinstrumentinpatientswithcovid19 AT reyescarolina contentvalidityandpsychometricpropertiesoftheinfluenzapatientreportedoutcomeplusfluproplusinstrumentinpatientswithcovid19 AT birchhelenj contentvalidityandpsychometricpropertiesoftheinfluenzapatientreportedoutcomeplusfluproplusinstrumentinpatientswithcovid19 AT raymondkimberly contentvalidityandpsychometricpropertiesoftheinfluenzapatientreportedoutcomeplusfluproplusinstrumentinpatientswithcovid19 AT gelhornheatherl contentvalidityandpsychometricpropertiesoftheinfluenzapatientreportedoutcomeplusfluproplusinstrumentinpatientswithcovid19 AT kosinskimark contentvalidityandpsychometricpropertiesoftheinfluenzapatientreportedoutcomeplusfluproplusinstrumentinpatientswithcovid19 AT sauciercoryd contentvalidityandpsychometricpropertiesoftheinfluenzapatientreportedoutcomeplusfluproplusinstrumentinpatientswithcovid19 AT mitchellfosterapril contentvalidityandpsychometricpropertiesoftheinfluenzapatientreportedoutcomeplusfluproplusinstrumentinpatientswithcovid19 AT lopuskiamanda contentvalidityandpsychometricpropertiesoftheinfluenzapatientreportedoutcomeplusfluproplusinstrumentinpatientswithcovid19 AT powersjohnh contentvalidityandpsychometricpropertiesoftheinfluenzapatientreportedoutcomeplusfluproplusinstrumentinpatientswithcovid19 |